Le Lézard
Classified in: Health
Subjects: CALENDAR OF EVENTS, Conference Calls/ Webcasts

Xenon Pharmaceuticals Announces Conference Call and Webcast to Discuss Second Quarter 2023 Financial Results and Provide Corporate Update


VANCOUVER, British Columbia, Aug. 02, 2023 (GLOBE NEWSWIRE) -- Xenon Pharmaceuticals Inc. (Nasdaq:XENE), a neurology-focused biopharmaceutical company, today announced it will report its second quarter 2023 financial and operating results after the close of U.S. financial markets on Wednesday, August 9, 2023.

Conference Call/Webcast Information:

Date:Wednesday, August 9, 2023
Time:4:30 pm Eastern Time (1:30 pm Pacific Time)
Dial-In:(800) 715-9871 or (646) 307-1963 for international callers
Conference ID:7071952
  

A live audio webcast will be available on the "Investors" section of Xenon's website and posted for replay following the event. The above listed dates and times are subject to change.

About Xenon Pharmaceuticals Inc.

Xenon Pharmaceuticals (NASDAQ:XENE) is a clinical stage biopharmaceutical company committed to developing innovative therapeutics to improve the lives of patients with neurological disorders. We are advancing a novel product pipeline of neurology therapies to address areas of high unmet medical need, with a focus on epilepsy. For more information, please visit www.xenon-pharma.com.

"Xenon" and the Xenon logo are registered trademarks or trademarks of Xenon Pharmaceuticals Inc. in various jurisdictions. All other trademarks belong to their respective owner.

Investor/Media Contact:
Jodi Regts
Xenon Pharmaceuticals Inc.
Phone: 604.484.3353
Email: [email protected]



These press releases may also interest you

at 12:35
Imagining Combat Without Military Medicine: What Would That Look Like?
The Friends of the Uniformed Services University (Friends of USU) will host a lunch and panel discussion on Wednesday, May 22, 12:00-2:30 p.m. at the National Press Club in Washington, DC., to discuss the history, present state, and future of...

at 12:30
InventHelp Inventor Develops Improved Powered Toothbrush (BEC-361)
"As a dental hygienist, I wanted to create a new brushing tool to prevent soft tissue damage and gum recession," said an inventor, from Albuquerque, N.M., "so I invented the D S POWER BRUSH. My toothbrush head design would reduce the pain and...

at 12:30
Advanced Prenatal Therapeutics Receives Breakthrough Innovation Award at the California Investment Forum 2024
Advanced Prenatal Therapeutics, Inc. ("APT") is pleased to have received the California Investment Forum (CIF) 2024 Innovation Award for Breakthrough Medical Technology in Diagnosis and Treatment in recognition of APT's breakthrough technology, the...

at 12:22
Novel non-addictive, non-toxic painkiller developed at LSU Health New Orleans
LSU Health New Orleans announces the discovery and clinical advancement of a new non-opioid therapeutic candidate for treatment of acute, chronic, and neuropathic pain and migraine headaches which does not have the organ toxicity or addiction...

at 12:20
PTC Therapeutics Announces European Commission Returns Translarnatm Opinion to CHMP For Re-evaluation
PTC Therapeutics, Inc. announced today that the European Commission (EC) has decided not to adopt the CHMP's negative opinion of Jan. 24, 2024, on the annual renewal of the conditional marketing authorization of Translarnatm (ataluren) and has...

at 12:20
Resurgia Health Solutions and Ennoble Care's Georgia Housecalls Practice Finalize Combination to Strengthen Healthcare Access in Georgia
Resurgia Health Solutions and Ennoble Care have united to strengthen healthcare access in Georgia. With no change in leadership, the merged practice will ensure continuity of care while providing more density, responsiveness, and resources to meet...

More news about Health...


News published on and distributed by: